Immunotherapy with local treatment for limited spread esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma.
- Your cancer has spread to 4 or fewer distant areas, with no more than 3 in any one organ, and each spot is 5 cm or smaller.
- You are in fairly good health, able to care for yourself (ECOG score 0-1).
- You have not had prior immunotherapy with PD-1 inhibitors, unless it was stopped more than 3 months ago for reasons other than side effects or worsening disease.
- Your blood counts and organ function tests are within a certain safe range.
- You do not have an active infection, autoimmune disease, or need steroids at the time of starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests a treatment approach that combines low-dose radiation with immunotherapy and chemotherapy for people with esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough to make surgery possible, which could improve outcomes.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
This trial tests whether adding targeted radiation or other local treatments can help people with esophageal cancer that has spread to only a few spots (up to 4) after they've been treated with a PD-1 inhibitor. It aims to control the cancer better and improve outcomes.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.